CLOSED
ACCREDITED INVESTORS ONLY
GET A PIECE OF FIBROBIOLOGICS
The Future of Cell Therapy
REASONS TO INVEST
Two years ago, FibroBiologics was spunout from its parent company, SpinalCyte, and is now a leading biopharma company focused on developing and commercializing fibroblast cell-based therapies in the fight against chronic diseases.
We’ve dedicated our attention to an overlooked and highly promising cell therapy using fibroblasts, which demonstrate similar characteristics to stem cells and are one of the most abundant cells in the human body.
Through our research and product development, we are fundamentally changing the current treatment paradigm and shaping the future for how we fight chronic disease.
THE PROBLEM & OUR SOLUTION
An Advantageous Alternative to Stem Cell Therapies
Up to this point, cell therapy research has primarily focused on the use of stem cells, with over 30 companies currently participating in the space, yet stem cells are not the only option for cell therapy treatment. Research has shown that fibroblasts have similar capabilities to stem cells, although fibroblasts are more readily available, more robust, and less expensive. They are also much easier to harvest, grow, store, and transport—all in all, improving outcomes and reducing patient barriers to access.
FibroBiologics is developing fibroblast cell therapy platform technology, with an extensive patent portfolio covering a wide range of clinical applications. The company is currently conducting research to discover potential breakthrough treatments and cures of chronic diseases, which we will continue to develop into product candidates by conducting clinical studies and trials to demonstrate safety and efficacy. We will generate revenues by either commercializing approved products on our own or by partnering with biopharma companies that will develop and commercialize these product candidates and pay us licensing revenues.
The company currently has five product candidates in the pipeline targeting different medical areas: multiple sclerosis ($24B market size), degenerative disc disease ($26B market size), wound healing ($17B market size), and extension-of-life applications. (source)
THE MARKET & OUR TRACTION
Medical Breakthroughs for Massive Market Potential
Anyone who’s been paying attention has seen the excitement and investment spurred by breakthroughs in stem cell research and accompanying medical advances—and for fibroblasts, we expect we’re looking at equally attractive potential.
Each of our product candidates exists within a multi-billion-dollar global market with enormous growth potential, thanks to increasing access on a global scale and aging populations. To date, FibroBiologics and our parent company, SpinalCyte, LLC, have raised $55M for the development of our intellectual property portfolio for fibroblast cell therapy, completed over 13 years of R&D, and we’ve secured or submitted over 150 patents (and counting).
As early as 2025, we may have an approved product in wound healing, and with adequate capital, we’ll initiate clinical trials for degenerative disc and multiple sclerosis treatments, as well as beginning discovery research in cancer and extension-of-life applications.
WHY INVEST
Invest in the Future of Treating Chronic Disease
The potential of our fibroblast cell-based therapy has game-changing health implications and potential opportunity for our investors. Your investment would bring us one step closer to a breakthrough in our treatment of chronic disease. Join us in leading the new era of cell therapy, and invest in FibroBiologics today!
Bonus Shares Disclosure: Up to 11,000,000 shares of Series B-1 Preferred Stock, consisting of (i) up to 10,000,000 shares of Series B-1 Preferred Stock at the Offering price of $5.00 per share and (ii) up to 1,000,000 shares of Series B-1 Preferred Stock representing bonus shares. These bonus shares will be awarded as an incentive for expeditious submission of investment documents. The term "expeditious submission" refers to the prompt provision of the necessary payment and documentation to validate the accredited status of the investor. Specifically, this involves the investor completing both the financial commitment and the submission of relevant documents required for accreditation status verification, all within a timeframe of seven business days. It is important to note that the determination of whether the submitted documentation adequately fulfills the accreditation verification requirements lies within the purview of the Company. This discretion empowers the Company to ensure compliance with applicable regulations and standards, maintaining the integrity of the investment process.
The offering is being conducted under Rule 506(c) of Regulation D, and the securities are being offered and sold only to accredited investors through general solicitation. An accredited investor is an individual or entity that meets specific income or net worth requirements as defined by the Securities and Exchange Commission.
The securities offered hereby have not been registered for sale under the Securities Act of 1933, as amended (the “Securities Act”) or registered under any state’s securities laws and may not be sold, transferred or otherwise disposed of unless they have been registered under the Securities Act and any applicable state securities laws or an exemption from registration is available.
ACCREDITED INVESTOR VERIFICATION: IN ACCORDANCE WITH THE REGULATIONS SET FORTH BY THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (SEC) UNDER RULE 506(C) OF REGULATION D, ALL PROSPECTIVE INVESTORS MUST BE VERIFIED AS ACCREDITED INVESTORS BEFORE THEY CAN INVEST IN THE OFFERING.
ALL PROSPECTIVE INVESTORS MUST BE VERIFIED AS ACCREDITED INVESTORS BEFORE THEY CAN INVEST AND PROVIDE INSTRUCTIONS ON HOW TO COMPLETE THE VERIFICATION PROCESS.
VERIFICATION OF ACCREDITED INVESTOR STATUS IS CRUCIAL TO ENSURE COMPLIANCE WITH APPLICABLE SECURITIES LAWS, PROTECT INVESTORS, AND MAINTAIN THE INTEGRITY OF THE 506(C) OFFERING. THIS VERIFICATION PROCESS CONFIRMS THAT INVESTORS MEET THE NECESSARY CRITERIA AND HAVE THE FINANCIAL SOPHISTICATION TO UNDERSTAND THE RISKS ASSOCIATED WITH THE INVESTMENT.
VERIFICATION PROCESS: TO COMPLETE THE ACCREDITED INVESTOR VERIFICATION PROCESS, PROSPECTIVE INVESTORS MUST FOLLOW THE INSTRUCTIONS PROVIDED BY THE ISSUER OR ITS AUTHORIZED REPRESENTATIVE. THESE INSTRUCTIONS MAY INCLUDE SUBMITTING RELEVANT DOCUMENTATION, SUCH AS FINANCIAL STATEMENTS, TAX RETURNS, OR VERIFICATION LETTERS FROM QUALIFIED PROFESSIONALS.
This offering is speculative and illiquid, and investors should be prepared to hold the securities for an indefinite period. Investing in securities involves risk, and there is the possibility of losing your entire investment. Neither StartEngine nor its affiliates provide investment advice or recommendations, nor do they offer legal or tax advice regarding any securities.
Investors should carefully review all offering documents, including the private placement memorandum, subscription agreement, and any other relevant materials before making an investment decision.
ANY FORWARD-LOOKING STATEMENTS MADE ON THE OFFERING PAGE ARE SUBJECT TO VARIOUS RISKS AND UNCERTAINTIES AND MAY NOT BE ACCURATE OR RELIABLE. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH STATEMENTS.
ABOUT
HEADQUARTERS
455 E. Medical Center Blvd, Suite 300
Houston, TX 77598
WEBSITE
View Site
ALL UPDATES
08.29.23
🚨REG D LIVE! 🚨We’re back!
The countdown is officially on! Last round (with different terms), FibroBiologics received an enormous amount of support on StartEngine, raising nearly $1M in their first 24 hours. 👀 Now, we’re back.
Our Reg D Campaign just launched, and you only have until September 1st to be a part of Fibrobiologics' groundbreaking journey before the next exciting step for our business rolls out.
Why Launch Day Matters:
Exclusive Entry: Secure your stake in FibroBiologics before the doors close to new investors.
Trailblazing Science: Watch your investment propel revolutionary fibroblasts solutions from concept to reality.
Ready to rise with us? Tap below to seize this moment and reach out to contact@startengine.com should you need any assistance! We also encourage you to schedule a call with StartEngine’s investor services team if you desire 1:1 assistance.
Thank you for being our launch partners in harnessing the power of fibroblasts.
To the stars and beyond,
Pete O’Heeron
CEO, Founder, and Chairman of FibroBiologics
Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of the entire investment.
REWARDS
$5,000
Bonus Share
Invest $5,000+ and receive 10% bonus shares. See PPM for Bonus Share Disclosure.
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
There are no restrictions for accredited investors.
When you invest, you are purchasing an interest in a Series LLC, which owns shares of the underlying company either directly or indirectly. You will not be purchasing shares in the underlying company itself.
A Series LLC, like StartEngine Private, is a parent LLC that includes multiple series, each of which holds interests in different underlying companies. The series either directly or indirectly invests in and holds shares of the underlying company. Each series will merely be a separate series and not a separate legal entity. Under Delaware law, if certain conditions are met, the liability of investors holding one series of interests is segregated from the liability of investors holding another series of interests, and the assets of one series of interests are not available to satisfy the liabilities of other series of interests. In the case of StartEngine Private, each series will be created for the purpose of holding an equity interest in stated underlying companies.
After the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward. Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
The Series of StartEngine Private purchases the underlying securities from an affiliate. The affiliate previously sourced and negotiated the terms to purchase these underlying securities from third parties. The amount paid by the Series is higher than the price the affiliate paid for the securities previously in the secondary market. We also note that while StartEngine does not impose any continuing management fee expenses, there is a carried interest of 20 percent associated with the investment in our series, and therefore, to the extent the securities appreciate in value, there will not be a one-to-one economic parity between the share value of the StartEngine Private shares and the company’s shares. Please read the “Risk Factors,” which is included as Exhibit B to the subscription agreement for further details.
In the event that an underlying company experiences a liquidity event, after the relevant holding period is over, either the proceeds from the sale of the shares will be distributed to investors, or if requested, the shares will be transferred to the investor’s brokerage account of choice, minus any applicable fund operating expenses or carried interest. Holding period length varies from company to company. Please note that we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
Investors are able to cancel their investment for 48 hours after submitting their investment. Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days. Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.
Regulation D 506(c) allows companies to raise an unlimited amount of capital from accredited investors through general solicitation and advertising, provided that all purchasers are verified as accredited investors. Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
In the US, an accredited investor includes anyone who:
- earned income that exceeded $200,000 (or $300,000 together with a spouse or spousal equivalent) in each of the prior two years and reasonably expects the same for the current year, or;
- has a net worth over $1 million, either alone or together with a spouse or spousal equivalent (excluding the value of the person’s primary residence), or;
- holds in good standing a Series 7, 65, or 82 license.
In the U.S., a "qualified purchaser" must meet a higher financial qualification than "accredited investor."
Individuals and certain entities may qualify as qualified purchasers. In order to be considered a qualified purchaser, you are required to have:
- $5+ million in investments for an individual, family business, or estate planning entity (e.g., certain trusts) excluding primary residences and business property.
- $25+ million in investments for an investment manager
Investments can include:
- Stocks
- Bonds
- Mutual funds
- Cash or cash equivalents
- Real estate (excluding primary residence or business property)
For more information, you can visit here and contact your financial advisor.
Please note: you can also have a Licensed Attorney, Licensed Accountant, Registered Broker-Dealer, or Registered Investment Advisor provide a letter affirming your accreditation.
Alternatively, the following information will be required:
- To verify your income: provide the last 2 years’ worth of tax documents that prove you have had sufficient income for the last two years to meet requirements.
- To verify your net worth: provide account statements, proof of property ownership, or other documentation showing ownership that proves you have a net worth that meets requirements.
- To verify your Series 7, 65, or 82 license: provide your FINRA CRD number for validation.
